全球最新、最好的创新药物，什么时候能来中国？跨国药企赛诺菲正在用实际行动表明，中国可以是全球新药"第一站"。 2025年12月到2026年1月，短短数周内，赛诺菲连续有两款心血管药物在中国获批。它们分别是全球首发的新药阿夫凯泰片（商品名：星舒平 ），有着同类 最佳潜力，以及全球首创的普乐司兰钠注射液（商品名：瑞达普 ），填补了一处重要疾病领域的治疗空白。 实际上，赛诺菲的"心血管双子星"接连获批，也是与中国合作伙伴深度交融的结果，也是赛诺菲创新的BD（business development，业务拓展）模式的明 证。 2025年，堪称中国创新药BD交易爆发元年。医药魔方数据显示，中国创新药BD出海授权2025年交易总金额达到1356.55亿美元，再创历史新高。 在中国创新药纷纷借船出海时，赛诺菲中国则另辟蹊径。2022年底，总部授权赛诺菲中国引进管线的权力。此后，赛诺菲立足中国，主动深入中国本土创新 药生态，发掘最有潜力的药物分子，凭借自身雄厚的开发和商业化实力，让药物最早惠及中国患者。 2024年末以来，赛诺菲分别通过与箕星药业、维亚臻的BD合作，获得了阿夫凯泰片和普乐司兰钠注射液的大中华区开发及商业化权益 ...

Core Insights - The article compares two small-cap growth ETFs, the Vanguard Small-Cap Growth ETF (VBK) and the iShares S&P Small-Cap 600 Growth ETF (IJT), focusing on their cost, performance, risk, and portfolio construction to assist investors in making informed decisions [1][2] Cost & Size Comparison - IJT has an expense ratio of 0.18%, while VBK has a lower expense ratio of 0.07% [3] - As of January 17, 2026, IJT's one-year return is 8.63%, compared to VBK's 12.47% [3] - IJT offers a dividend yield of 0.91%, higher than VBK's 0.54% [3] - Assets under management (AUM) for IJT is $6 billion, while VBK has significantly higher AUM at $39 billion [3] Performance & Risk Comparison - Over the past five years, IJT experienced a maximum drawdown of -29.23%, while VBK had a deeper drawdown of -38.39% [4] - An investment of $1,000 in IJT would have grown to $1,227 over five years, while the same investment in VBK would have grown to $1,155 [4] Portfolio Composition - VBK holds 552 positions, with 27% allocated to technology, 21% to industrials, and 18% to healthcare, featuring top holdings like Insmed and SoFi Technologies [5] - IJT contains 348 stocks, with a more balanced sector allocation: 20% in technology, 19% in industrials, and 17% in healthcare, including leading positions like Arrowhead Pharmaceuticals [6] Investment Implications - Both ETFs focus on small-cap stocks with growth potential, which may lead to higher total returns over time [7] - VBK is considered slightly higher risk due to its heavier tilt towards technology, indicated by a higher beta of 1.43 compared to IJT's 1.18 [8] - IJT's higher dividend yield may appeal to income-focused investors, despite its higher expense ratio compared to VBK [9] - Investors must weigh their goals, as VBK has shown larger price swings but has outperformed IJT over the last 12 months [10]

Core Insights - The article compares two small-cap ETFs: iShares Morningstar Small-Cap ETF (ISCB) and State Street SPDR Portfolio S&P 600 Small Cap ETF (SPSM), highlighting their differences in portfolio breadth, costs, and performance [4]. Group 1: ETF Overview - ISCB tracks 1,578 small-cap U.S. stocks, with sector weights in industrials (19%), financial services (17%), and healthcare (13.9%) [2]. - SPSM holds 607 U.S. small-cap stocks, with a sector tilt towards financial services (18%), industrials (16%), and technology (15%) [1]. Group 2: Performance and Cost - ISCB has performed slightly better over the last five years, showing more growth and a smaller maximum drawdown compared to SPSM [7]. - SPSM offers a lower expense ratio and a higher dividend yield, making it attractive for cost-conscious investors [3][7]. Group 3: Sector Exposure - ISCB's inclusion of healthcare among its top sectors may appeal to investors looking for defensive opportunities, while SPSM's higher concentration in technology may attract those wanting to capitalize on tech sector trends [8].

Core Insights - Aligos Therapeutics has appointed James Hassard as Executive Vice President and Chief Commercial Officer to enhance its global commercial capabilities [1][2] - The company is advancing the Phase 2 B-SUPREME study of pevifoscorvir sodium and is preparing for its commercial launch [2] - Aligos focuses on developing therapies for liver and viral diseases, with a strong emphasis on chronic hepatitis B virus infection and other high unmet medical needs [3] Company Overview - Aligos Therapeutics, Inc. is a clinical stage biotechnology company dedicated to improving patient outcomes through innovative therapies for liver and viral diseases [3] - The company utilizes a science-driven approach and has a purpose-built pipeline targeting conditions such as chronic hepatitis B virus infection, obesity, metabolic dysfunction-associated steatohepatitis, and coronaviruses [3] Leadership Background - James Hassard brings extensive experience in building commercial organizations across various therapeutic areas, having previously served as Chief Commercial Officer at Crinetics Pharmaceuticals and Arrowhead Pharmaceuticals [2] - His career includes significant roles at Coherus Oncology, Amgen, and Merck, where he launched multiple pharmaceutical products in areas including hepatitis, oncology, and nephrology [2] - Hassard holds a Bachelor of Science in Pharmacology and an MBA, indicating a strong educational background relevant to his new role [2]

Company Overview - Arrowhead Pharmaceuticals is identified by the ticker symbol ARWR, with a stock price of $64.56 as of the last trading day [3] - The company has approximately 136 million shares outstanding, resulting in a market capitalization of around $9 billion [3] - As of the latest filing, Arrowhead has about $920 million in cash and investments, excluding $200 million from Sarepta that has been invoiced but not yet received, and $200 million from Novartis that has been received but not yet reflected in filings [3] Business Focus - The primary objective of Arrowhead Pharmaceuticals is to bring RNA interference technology to patients [4] - The company has achieved its first commercial launch with the product REDEMPLO, which has been approved in both the U.S. and Canada [4]

Arrowhead Pharmaceuticals FY Conference Summary Company Overview - **Company Name**: Arrowhead Pharmaceuticals - **Ticker Symbol**: ARWR - **Market Capitalization**: Approximately $9 billion with 136 million shares outstanding [2] - **Cash and Investments**: Approximately $920 million, excluding additional funds from Sarepta and Novartis [2] Core Business and Pipeline - **Focus**: Development of RNA interference (RNAi) therapies targeting various diseases [3] - **First Commercial Launch**: Rudemplo, approved in the US, Canada, and China for lowering triglycerides in patients with familial chylomicronemia syndrome (FCS) [3] - **Pipeline**: 20 clinical stage programs, including 11 wholly owned and 9 partnered candidates [3] - **Expected Growth**: Aim to add 2-3 additional drug candidates annually [3] Key Products and Indications Rudemplo - **Indication**: Treatment of FCS, with ongoing studies for severe hypertriglyceridemia (SHTG) [7] - **Efficacy**: Achieved approximately 80% reduction in triglyceride levels in clinical studies [9] - **Market Potential**: Targeting approximately 6,500 FCS patients in the US and a broader SHTG population of about 3 million [11][12] Zodasiran - **Indication**: Treatment of homozygous familial hypercholesterolemia (HoFH) [12] - **Efficacy**: Demonstrated a 41% reduction in LDL cholesterol in HoFH patients [13] - **Market Potential**: Estimated 1,000 to 2,000 patients in the US with HoFH [13] ARO-Dimer-PA - **Indication**: Designed to treat mixed hyperlipidemia by silencing both ApoC3 and PCSK9 [15] - **Market Potential**: Approximately 20 million patients in the US with elevated LDL cholesterol and triglycerides [16] Obesity Candidates (ARO-INHBE and ARO-ALK7) - **Focus**: Targeting specific pathways to reduce visceral fat and improve metabolic outcomes [18] - **Efficacy**: ARO-INHBE showed a 9.9% reduction in visceral fat after 16 weeks [20] - **Combination Therapy**: ARO-INHBE combined with tirzepatide resulted in a 9.4% weight loss compared to 4.8% with tirzepatide alone [20] CNS Program (ARO-MAPT) - **Indication**: Targeting tau protein for Alzheimer's and tauopathies [25] - **Efficacy**: Early data shows potential for significant tau reduction in animal models [26] - **Market Potential**: Addressing a significant unmet need in neurodegenerative diseases [25] Financial Strategy and Market Position - **Pricing Strategy**: Rudemplo priced at $60,000 for both FCS and SHTG populations to ensure payer acceptance and long-term market access [36] - **Cash Management**: Strong financial position with over $900 million available to fund ongoing and future trials [47] - **Regulatory Pathways**: Potential for expedited approval based on LDL reduction for ARO-Dimer-PA [45] Upcoming Milestones - **Phase 3 Studies**: Expected readouts for SHTG in Q3 2026 and filing for SNDA in Q4 2026 [28] - **Obesity Pipeline Expansion**: Continued development of ARO-INHBE and ARO-ALK7 with additional data expected throughout 2026 [29] - **CNS Pipeline**: Initial data for ARO-MAPT anticipated in late Q3 2026 [29] Conclusion Arrowhead Pharmaceuticals is positioned to capitalize on significant market opportunities in the RNAi space, with a robust pipeline targeting high unmet medical needs across various therapeutic areas. The company’s strategic focus on pricing, cash management, and regulatory pathways aims to enhance its market presence and drive future growth.

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are highlighted, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is presented as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is characterized as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and positioned to capitalize on the onshoring trend driven by tariffs [5][6] Financial Position - The company is noted for being debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization, which provides a strong financial foundation [8][10] - It also has a substantial equity stake in another AI-related venture, offering investors indirect exposure to multiple growth opportunities without the associated premium costs [9] Market Trends - The article discusses the broader trends of AI, energy, tariffs, and onshoring, emphasizing the interconnectedness of these sectors and the company's strategic positioning within them [6][14] - The influx of talent into the AI sector is mentioned, indicating a continuous stream of innovation and advancements that will drive future growth [12] Future Outlook - The potential for significant returns is highlighted, with projections suggesting a possible 100% return within 12 to 24 months for investors who act quickly [15][19] - The company is described as undervalued, trading at less than seven times earnings, which presents a compelling investment opportunity in the context of the AI and energy sectors [10][11]

Company Overview - Arrowhead Pharmaceuticals is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapeutics targeting serious diseases, particularly liver disorders and cardiometabolic conditions [8][9] - The company has a robust clinical pipeline that includes drug candidates such as ARO-AAT, ARO-APOC3, and JNJ-3989, and generates revenue through licensing agreements, research collaborations, and milestone payments from pharmaceutical partners [8][9] - As of the most recent financial data, Arrowhead Pharmaceuticals has 609 employees, a total revenue of $829.45 million, and a net income of -$1.63 million for the trailing twelve months (TTM) [5] Recent Developments - On December 17, 2025, CEO Christopher Richard Anzalone sold 85,000 shares of Arrowhead Pharmaceuticals for approximately $5.44 million, which aligns with his historical trading activity [1][2][7] - The sale occurred during a period of significant stock performance, with a total return of 249.37% over the prior year, and the stock closing at $64.80 on the transaction date [2][12] - The timing of the sale suggests it was part of a tax-planning strategy related to performance awards that vested in December [4][11] Market Context - The stock price surged following the FDA approval of Arrowhead's first medicine, plozasiran (marketed as Redemplo), for treating familial chylomicronemia syndrome, reaching a 52-week high of $76.76 on January 6 [12] - The current elevated price-to-sales ratio indicates that while it may be a good time for shareholders to sell, waiting for a price drop before reinvesting could be a more strategic approach [13] Competitive Edge - Arrowhead Pharmaceuticals' competitive advantage lies in its proprietary RNAi delivery technologies, which enable the treatment of previously untreatable diseases [10]

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the advancements in the small nucleic acid drug sector, particularly focusing on companies like Wave Life Sciences and Arrowhead Pharmaceuticals, which have shown promising data in weight loss and fat reduction therapies [1][4][5]. Core Insights and Arguments - **Advantages of Small Nucleic Acid Drugs**: These drugs demonstrate long-lasting effects, improved safety by reducing the dosage of GLP-1 drugs, and the ability to achieve high-quality weight loss by specifically targeting visceral fat while preserving lean body mass [1][5]. - **Clinical Developments**: Key catalysts for 2026 include advancements in major indications such as severe hypertriglyceridemia (SHTG), cardiovascular outcomes related to LPA, and IgA nephropathy. Arrowhead's OX7 data is expected to show significant clinical changes in humans [1][8]. - **Market Position of Chinese Companies**: Chinese firms are leveraging engineering advantages to enhance specificity and delivery efficiency, positioning themselves to develop best-in-class molecules, particularly in non-liver diseases [1][9]. - **Emerging Targets in Hyperlipidemia**: New targets like LP(a) are gaining attention, with major Chinese pharmaceutical companies like Hengrui and Shiyao licensing oral small molecule LP(a) inhibitors to multinational corporations for approximately $2 billion each [3][20]. Additional Important Content - **Recent Progress in Small Nucleic Acid Research**: Recent data from Wave Life Sciences and Arrowhead Pharmaceuticals confirm the efficacy of small nucleic acid drugs in weight loss and fat reduction, with significant results observed in clinical trials [4][24]. - **Commercialization and Development Trends**: The small nucleic acid drug sector has seen a resurgence since 2016, with successful commercialization efforts leading to substantial market valuations, such as Alnylam's peak market cap of $60 billion [17][18]. - **Challenges in Delivery Systems**: While advancements have been made in delivery systems, many remain in early stages, indicating a need for further innovation to enhance efficacy and safety in non-liver delivery systems [16][24]. - **Trends in MNC Transactions**: There is a notable trend of large pharmaceutical companies showing interest in early-stage small nucleic acid drugs, with significant transaction values even at the preclinical stage, indicating strong market confidence [19]. This summary encapsulates the critical developments and insights from the conference call, highlighting the potential and challenges within the small nucleic acid drug industry.

Core Viewpoint - Arrowhead Pharmaceuticals, Inc. has announced the pricing of its concurrent public offerings, which include $625 million in convertible senior notes and 3,100,776 shares of common stock priced at $64.50 per share [1] Group 1: Public Offerings - The company is offering $625,000,000 aggregate principal amount of 0.00% convertible senior notes due in 2032 [1] - Additionally, the company is offering 3,100,776 shares of common stock at a public offering price of $64.50 per share [1] - For certain investors, pre-funded warrants are available at a public offering price of $64.499 per warrant, for up to 1,550 [1]